GATA3 Monoclonal Antibody [1C1] 100 µg
- Known as:
- GATA3 Monoclonal Antibody [1C1] 100 µg
- Catalog number:
- ABB-2238-100
- Product Quantity:
- 100 µg
- Category:
- -
- Supplier:
- EpigenTek
- Gene target:
- GATA3 Monoclonal Antibody [1C1] 100 µ
Related genes to: GATA3 Monoclonal Antibody [1C1] 100 µg
- Gene:
- C1orf174 NIH gene
- Name:
- chromosome 1 open reading frame 174
- Previous symbol:
- -
- Synonyms:
- RP13-531C17.2
- Chromosome:
- 1p36.32
- Locus Type:
- gene with protein product
- Date approved:
- 2005-07-21
- Date modifiied:
- 2017-07-11
- Gene:
- CBR1 NIH gene
- Name:
- carbonyl reductase 1
- Previous symbol:
- CBR
- Synonyms:
- SDR21C1
- Chromosome:
- 21q22.12
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-20
- Date modifiied:
- 2016-10-05
- Gene:
- DLG1 NIH gene
- Name:
- discs large MAGUK scaffold protein 1
- Previous symbol:
- -
- Synonyms:
- SAP97, SAP-97, hdlg, DLGH1, dJ1061C18.1.1
- Chromosome:
- 3q29
- Locus Type:
- gene with protein product
- Date approved:
- 1995-05-04
- Date modifiied:
- 2016-05-24
- Gene:
- DNAAF4 NIH gene
- Name:
- dynein axonemal assembly factor 4
- Previous symbol:
- DYX1C1
- Synonyms:
- EKN1, FLJ37882, CILD25
- Chromosome:
- 15q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-10-10
- Date modifiied:
- 2017-03-20
- Gene:
- DNAAF4-CCPG1 NIH gene
- Name:
- DNAAF4-CCPG1 readthrough (NMD candidate)
- Previous symbol:
- DYX1C1-CCPG1
- Synonyms:
- -
- Chromosome:
- 15q21.3
- Locus Type:
- readthrough
- Date approved:
- 2011-09-23
- Date modifiied:
- 2017-03-23
Related products to: GATA3 Monoclonal Antibody [1C1] 100 µg
Related articles to: GATA3 Monoclonal Antibody [1C1] 100 µg
- This study aimed to classify upper tract urothelial carcinoma (UTUC) using GATA3, KRT5, and P16 immunohistochemistry and to evaluate associations of these molecular subtypes with clinicopathological features and outcomes. - Source: PubMed
Publication date: 2026/10/06
Yang JiayuYu WentaoZhang ShengwangChen Qian - Site-of-origin immunohistochemistry is widely used in the evaluation of metastatic carcinoma, but lineage-associated markers are neither completely sensitive nor entirely specific. This review examines diagnostically important patterns of immunophenotypic discordance, with emphasis on aberrant marker expression and loss of expected lineage-associated proteins. Biological mechanisms include dedifferentiation, lineage plasticity, metastatic selection, intratumoral heterogeneity, and treatment-associated reprogramming, whereas fixation, decalcification, antibody clone, assay conditions, staining interpretation, and limited sampling may create analytical or interpretive pseudodiscordance. Particular attention is given to PAX8; GATA3, TRPS1, and SOX10; TTF-1 and Napsin A; CDX2 and SATB2; and NKX3.1, PSMA, PSA, and PSAP. The review also outlines a practical approach to conflicting results based on reassessment of morphology, verification of technical credibility, use of limited complementary panels, comparison with prior material, and clinicoradiologic correlation. Molecular tissue-of-origin profiling may provide ancillary diagnostic support when clinicopathologic findings remain unresolved. Comprehensive genomic profiling serves a distinct treatment-oriented role by identifying potentially actionable molecular alterations. Overall, discordant immunophenotypes should modify diagnostic probability rather than determine site of origin in isolation. - Source: PubMed
Publication date: 2026/10/02
Gadkari PravinVagha Sunita - We describe a case of breast metastasis originating from a small-cell neuroendocrine carcinoma (SCNEC) of the uterine cervix, an uncommon presentation that can be difficult to distinguish from a primary breast malignancy. We report a 29-year-old woman treated three years earlier for FIGO stage IB2 cervical SCNEC with chemotherapy, surgery, and radiotherapy, who presented with a 1.5-cm mass in the left breast. Imaging suggested a primary breast malignancy, but her oncologic history raised concern for metastasis. Core-needle biopsy showed a high-grade small-cell neoplasm expressing synaptophysin, chromogranin A, and CD56, with a high Ki-67 index (>80%); breast-lineage markers, including GATA3 and mammaglobin, were negative. Whole-body fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) showed an isolated hypermetabolic breast lesion without other disease. Nipple-sparing mastectomy with immediate reconstruction was performed, followed by platinum-etoposide chemotherapy; at 18 months, there was no evidence of recurrence. Breast metastasis from cervical SCNEC can mimic primary breast cancer; diagnosis relies on integrating clinical history, imaging, and immunohistochemistry. Selected patients with isolated disease may benefit from individualised multimodal therapy. - Source: PubMed
Publication date: 2026/09/02
Bruyninx GladysPatocskai EricaSanchez Lilia MariaEl Khoury MonaKaviani Ahmad - A subgroup of GATA3-positive silent corticotroph adenomas (SCA) was identified by transcriptomics. We aimed to compare clinical, radiological and surgical outcomes of SCA with and without GATA3. - Source: PubMed
Publication date: 2026/10/03
Lamback Elisade Sousa Costa RangelWildemberg Luiz EduardoGadelha Mônica R - The full morphologic spectrum of divergent differentiations in urothelial carcinoma is still unknown. Herein, we describe two cases of pilomatrix-like high grade carcinomas (PiMLC) involving bladder. Case #1 was a 55-year-old male with a bladder tumor with basaloid nests, geographic necrosis, and shadow cells. The tumor cells were positive for LEF1, β-catenin (nuclear/cytoplasmic staining), CK5/6, CD10, BerEP4, p63 (focal-to-patchy) and AMACR (patchy), and negative for CK7, GATA3, CDX2, INSM1, chromogranin, synaptophysin, p40, CK20, calponin, CD117, S100, smooth muscle actin, p16 and high-risk HPV in-situ hybridization. PD-L1 and Her2 were negative. Trop-2 immunostain showed modest expression (H-score: 75). There were rare microscopic foci of surface disease with a similar basaloid appearance that were also positive for LEF1 and negative for GATA3. Genomic profiling of the tumor revealed an APC mutation, suggesting β-catenin/Wnt pathway dysregulation. Additionally, mutations in TERT, CDKN2A, and TP53 were present. The patient was transitioned to hospice shortly after initiating chemotherapy. Case #2 was a 78-year-old male with a large bladder mass with basaloid nests and abundant shadow cells. Conventional UC was focally present. The tumor cells were positive for p63, β-catenin (nuclear/cytoplasmic staining), CK14 (focal), and CK20 (focal), and negative for GATA3, Uroplakin, NUT, and Her2. Genomic profiling of the tumor revealed a CTNNB1 mutation, suggesting β-catenin/Wnt pathway dysregulation. Additionally, mutations in RB1, KMT2A, and TP53 were present. Overall, these two cases describe PiMLC of urinary bladder with evidence supporting novel pilomatrix-like divergent differentiation from urothelial carcinoma. - Source: PubMed
Publication date: 2026/10/03
Hu ElaineLammert Sarah MaeDavids TrentBennett Jennifer APaner Gladell PWang PengTjota Melissa YuwonoAntic TatjanaHartmann ArndtAgaimy AbbasKwon Jung Woo